Biomedical Science and Research Journals | Editorial on Carcinoma Prostate
Editorial on Carcinoma Prostate
Editorial
When healthy and normal cells in the body change and grow
out of control it forms a cancer. There are different kinds of cancers.
Most common are the breast Cancer, thyroid cancer and prostate
cancer. Breast cancer and prostate cancer spread to bones most
commonly. A cancer can be a benign cancer or a malignant cancer. A
malignant tumour has a metastatic spread that is it spread to other
organs whereas a benign cancer can grow but cannot spread [1].
Prostate cancer is one the unusual yet very common cancer
affecting most of the population. It is different from rest of the
cancers as it doesn’t spread quickly to other parts of body. Mostly
the prostate cancer is slowly growing and doesn’t cause any
obvious sign and symptoms. The usual symptoms are frequent
and painful micturation, burning micturation, blood in urine and
seminal fluid, weak and interrupted urine flow and new onset of
erectile dysfunction [2]. Prostate cancer is somewhat unusual when
compared with other types of cancer. This is because many prostate
tumours do not spread quickly to other parts of the body. Some
prostate cancers grow very slowly and may not cause symptoms or
problems for years.
Usually the early stage of prostate cancer has no signs and
symptoms. It is usually detected via DRE or PSA test. If it suggests
of having a Carcinoma prostate than further testing is carried out
[3]. A significant Research is being carried out for early detection of
prostate cancer and its linkage between the nutrition and lifestyle
factors. New genomic tests have been introduced by researchers for
its proper management [4].
Till date there are a lot of treatment options which include
Radiotherapy, chemotherapy and anti cancer drugs. For advanced
metastatic cancer especially to bones a lot of quantitative
parameters have been introduced, which include %PAB (Positive
area on bone scans), %BSI (Bone scan index), BLS (bone Lesion
scoring) and EOD (Extent of Disease). These methods help in
quantifying the tumour burden on bone scans which ultimately
helps in the modification of treatment plan [5].
Comments
Post a Comment